UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup.
D'Hondt V, Canon JL, Roca L, Levy C, Pierga JY, Le Du F, Campone M, Desmoulins I, Goncalves A, Debled M, Rios M, Ferrero JM, Serin D, Hardy-Bessard AC, Piot G, Brain E, Dohollou N, Orfeuvre H, Lemonnier J, Roché H, Delaloge S, Dalenc F.
D'Hondt V, et al. Among authors: roca l.
Eur J Cancer. 2019 Nov;122:91-100. doi: 10.1016/j.ejca.2019.09.014. Epub 2019 Oct 18.
Eur J Cancer. 2019.
PMID: 31634648
Clinical Trial.